Which trial do we need? A collaborative platform trial for cutaneous leishmaniasis amongst international travellers.

Cutaneous leishmaniasis (CL) is a vector-borne disease that affects up to 1 million individuals each year in over 100 endemic countries. The global burden is increasing [ [1] Burza S. Croft S.L. Boelaert M. Leishmaniasis. Lancet. 2018; 392: 951-970https://doi.org/10.1016/S0140-6736(18)31204-2 Abstract Full Text Full Text PDF PubMed Scopus (923) Google Scholar , [2] WHO | WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases - Leishmaniasis. WHO 2015. Google Scholar ], with CL among the top five diagnoses in international travellers evaluated for dermatological syndromes.[ [3] Boggild A.K. Caumes E. Grobusch M.P. Schwartz E. Hynes N.A. Libman M. et al. Cutaneous and Mucocutaneous Leishmaniasis in Travelers and Migrants: A 20-year GeoSentinel Surveillance Network Analysis. J Travel Med. 2019; https://doi.org/10.1093/jtm/taz055 Crossref Scopus (32) Google Scholar , [4] Pavli A. Maltezou H.C. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis. 2010; 14: e1032-1039https://doi.org/10.1016/j.ijid.2010.06.019 Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar ].